BioCentury
ARTICLE | Finance

Domain finds unmet need in CF

Unmet need drives Domain's investment in Celtaxsys, its first in CF

June 15, 2015 7:00 AM UTC

Domain Associates has decided the best way to play the cystic fibrosis space is to find a molecule that can be combined with the ever-increasing number of cocktails emerging from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). To do so, Domain led a $40 million series D round for Celtaxsys Inc. last week, marking its first investment in CF.

Celtaxsys' CTX-4430 is a once-daily oral inhibitor of leukotriene A4 hydrolase (LTA4H) that is expected to start Phase II testing next half to preserve lung function in CF patients. ...